The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2023

Filed:

Sep. 03, 2019
Applicants:

The University of North Carolina AT Charlotte, Charlotte, NC (US);

Oncotab, Inc., Charlotte, NC (US);

Inventors:

Pinku Mukherjee, Waxhaw, NC (US);

Jordon Wang, San Carlos, CA (US);

Kexin Huang, San Mateo, CA (US);

Yan He, Hayward, CA (US);

Assignees:

The University of North Carolina at Charlotte, Charlotte, NC (US);

OncoTab, Inc., Charlotte, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 49/00 (2006.01); A61K 47/68 (2017.01); A61K 45/06 (2006.01); A61K 9/51 (2006.01);
U.S. Cl.
CPC ...
A61K 49/0058 (2013.01); A61K 45/06 (2013.01); A61K 47/6883 (2017.08); A61K 9/51 (2013.01);
Abstract

Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.


Find Patent Forward Citations

Loading…